Nutrição e Esteatose Hepática não alcoólica – Artigo 15
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the hepatic consequence of metabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. The connection between gut microbiota (GM) and NAFLD has attracted significant attention in recent years. Data has shown that GM affects hepatic lipid metabolism and influences the balance between pro/anti-inflammatory effectors in the liver. Although studies reveal the association between GM dysbiosis and NAFLD, decoding the mechanisms of ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 14
Perfluoroalkyl substances and severity of nonalcoholic fatty liver in Children: An untargeted metabolomics approach
ABSTRACT
Background: Toxicant-associated steatohepatitis has been described in adults but less is known regarding the role
of toxicants in liver disease of children. Perfluoroalkyl substances (PFAS) cause hepatic steatosis in rodents, but
few previous studies have examined PFAS effects on severity of liver injury in children.
Objectives: We aimed to examine the relationship of PFAS to histologic severity of nonalcoholic fatty liver disease (NAFLD) in children.
Methods: ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 13
Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments
Abstract: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders worldwide. It is associated with clinical states such as obesity, insulin resistance, and type 2 diabetes, and covers a wide range of liver changes, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma. Metabolic disorders, such as lipid accumulation, insulin resistance, and inflammation, have been implicated in the pathog...
Nutrição e Esteatose Hepática não alcoólica – Artigo 12
Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations
Abstract: The progression of liver disease is portrayed by several common, overarching signs and symptoms. Classically, these include findings such as spider angiomata, jaundice, palmar erythema, and as cirrhosis decompensates, ascites, variceal hemorrhage (VH), hepatic encephalopathy (HE), and hepatocellular carcinoma (HCC). Aside from these universal hallmarks among cirrhotics, patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) harbor ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 11
Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
SUMMARY
We review the contribution of micronutrients to nonalcoholic fatty liver disease pathology and therapeutics. We
examine the relevant data on minerals, vitamins, and carotenoids in nonalcoholic fatty liver disease experimental
and human studies and offer insight into their use (or nonuse) therapeutically.
Micronutrients include electrolytes, minerals, vitamins, and carotenoids, and are required in microgram or milligram quantities for cellular metabolism. The liver plays an important role in micronutrient ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 10
Lipid Modulating Anti-oxidant Stress Activity of Gastrodin on Nonalcoholic Fatty Liver Disease Larval Zebrafish Model
Abstract: Non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is the most common chronic liver disease in the world. However, there are still no drugs for NAFLD/NASH in the market. Gastrodin (GAS) is a bioactive compound that is extracted from Gastrodia elata, which is used as an active compound on nervous system diseases. Recent reports showed that GAS and Gastrodia elata possess anti-oxidant activity and lipid regulating effects, which ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 9
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
Abstract: The gut microbiota plays critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes(T2D), and insulin resistance(IR), highlighting the potential of gut microbiota-targeted therapies in these diseases. There are various ways that gut microbiota can be manipulated, including through use of probiotics, prebiotics, synbiotics, antibiotics, and some active components from herbal medicines. In this review, we review the ...
Nutrição e Esteatose Hepática não alcoólica – Artigo 8
Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a common disease in Western society and ranges from steatosis to steatohepatitis to end-stage liver disease such as cirrhosis and hepatocellular carcinoma. The molecular mechanisms that are involved in the progression of steatosis to more severe liver damage in patients are not fully understood. A deeper investigation of NAFLD pathogenesis is possible due to the many different animal models developed ...
